In osteosarcoma cells, RHPS4 effectiveness seems to be unlinked from both the genetic status of ATRX and the active TMM, as demonstrated by the very similar sensitivity of HOS telomerase-positive cells to the compound (IC50 value: 1.2 μM). This evidence concerns the gene ATRX and osteosarcoma.